|Bid||128.00 x 1200|
|Ask||142.67 x 1300|
|Day's Range||139.82 - 143.09|
|52 Week Range||113.52 - 154.44|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||13.67|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bruce Cozadd became the CEO of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in 2009. First, this article will compare CEO...
Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day
Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday. Solriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), the EMA's human medicines committee (CHMP) said https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019. The drug was approved in the United States earlier this year and is part of the company's attempts to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, which faced a setback last year.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jazz (JAZZ) delivered earnings and revenue surprises of 14.21% and 2.87%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) reports narrower-than-expected third-quarter loss and beats revenue estimates. The company is set to initiate the FDA recommended phase III study on mirvetuximab soravtansine by year-end.
Allergan's (AGN) key products like Botox are likely to have provided top-line support in Q3 as loss of exclusivity of several products hurts sales.
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q3 results.
Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.